Biomedical Center (BMC), Metabolic Biochemistry, Ludwig-Maximilians-University, Munich, Feodor-Lynen-Str. 17, 81377 Munich, Germany.
Department of Aging Neurobiology, National Center for Geriatrics and Gerontology, Morioka-cho 7-430, 474-8511 Obu, Japan; Department of Mental Health Promotion, Osaka University Graduate School of Medicine, Machikaneyama-cho 1-17, 560-0043 Toyonaka, Japan.
Curr Opin Neurobiol. 2020 Apr;61:73-81. doi: 10.1016/j.conb.2020.01.011. Epub 2020 Feb 24.
Neurotoxic amyloid-β peptide (Aβ) 42/43 species generated by β-secretase and γ-secretase from the β-amyloid precursor protein (APP) are believed to trigger Alzheimer's disease (AD). Relative increases of these species due to mutations in APP and presenilin/γ-secretase are associated with the vast majority of early onset familial AD cases. Important breakthroughs have recently been made in elucidating the mechanism(s) of these mutations, showing that altered substrate interactions and substrate-enzyme complex stabilities are underlying their pathogenic Aβ generation. Moreover, first structures of γ-secretase in complex with APP and Notch1 substrates allow insight into how substrate cleavage could be initiated and further progress has been made in the mechanistic understanding of γ-secretase modulators, advanced Aβ-lowering drugs. These insights could be exploited for future AD clinical trials.
神经毒性淀粉样β肽(Aβ)42/43 物种由β-淀粉样前体蛋白(APP)中的β-分泌酶和γ-分泌酶产生,被认为是引发阿尔茨海默病(AD)的原因。由于 APP 和早老素/γ-分泌酶的突变,这些物种的相对增加与绝大多数早发性家族性 AD 病例有关。最近在阐明这些突变的机制方面取得了重要突破,表明改变的底物相互作用和底物-酶复合物稳定性是其致病 Aβ产生的基础。此外,与 APP 和 Notch1 底物结合的 γ-分泌酶的首个结构允许深入了解底物切割如何被启动,并且在 γ-分泌酶调节剂的机制理解方面取得了进一步进展,这些调节剂是先进的降低 Aβ药物。这些见解可以为未来的 AD 临床试验所利用。